BidaskClub lowered shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) from a hold rating to a sell rating in a research note issued to investors on Wednesday, July 19th.
A number of other equities analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, July 11th. Noble Financial reissued a buy rating on shares of Adamas Pharmaceuticals in a research note on Friday, May 12th. Mizuho reissued a buy rating and set a $26.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 6th. Finally, Cowen and Company reissued an outperform rating and set a $45.00 target price on shares of Adamas Pharmaceuticals in a research note on Sunday, May 28th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Adamas Pharmaceuticals has an average rating of Hold and a consensus price target of $29.00.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded down 3.93% during mid-day trading on Wednesday, hitting $14.68. 932,879 shares of the company’s stock traded hands. The firm has a 50-day moving average of $17.19 and a 200 day moving average of $16.86. Adamas Pharmaceuticals has a 52 week low of $12.10 and a 52 week high of $19.50. The company’s market cap is $330.51 million.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by $0.12. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. During the same quarter last year, the firm posted ($0.78) EPS. Adamas Pharmaceuticals’s revenue for the quarter was down 90.9% on a year-over-year basis. Equities research analysts predict that Adamas Pharmaceuticals will post ($3.71) EPS for the current year.
In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of Adamas Pharmaceuticals stock in a transaction on Monday, June 19th. The shares were sold at an average price of $17.05, for a total value of $5,967,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 731,041 shares of company stock valued at $12,476,149. Insiders own 29.00% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new stake in Adamas Pharmaceuticals during the second quarter valued at $109,000. American International Group Inc. increased its stake in Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after buying an additional 682 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in Adamas Pharmaceuticals during the second quarter valued at approximately $184,000. Wells Fargo & Company MN increased its stake in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after buying an additional 3,358 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in Adamas Pharmaceuticals during the first quarter valued at approximately $287,000. 70.86% of the stock is owned by hedge funds and other institutional investors.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
